Researchers in the United States, Canada & Europe are testing Colchicine on approximately 6,000 participants for a period of 30 days.
The trial is to find out whether short-term treatment with colchicine will reduce lung complications and the rate of death in COVID-19 patients.
Colchicine is thought to decrease the ‘cytokine storm’ or inflammation that causes complications and death, in patients with COVID-19.
Colchicine has also currently been approved by FDA for gout and familial mediterranean fever.
